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Interleukin-1 receptor antagonist allele: Is it a genetic link between
Henoch-Schdnlein nephritis and IgA nephropathy? Henoch-SchOnlein
purpura nephritis (HSPN) is a multi-organ systemic vasculitis, which
shares many clinical, histological and immunological features with IgA
nephropathy (IgAN). To address whether these two diseases have a
common genetic background, the polymorphism of the variable number
tandem repeat (VNTR) of IL-i receptor antagonist (IL-Ira) gene has
been analyzed using PCR in patients diagnosed with HSPN (N = 43) and
IgAN (N = 97), together with normal controls (N = 98) and patients with
acute post-infectious glomerulonephritis (APGN), under the concept that
IL-i might play an important role in mediating pathogenesis of vasculitis
and glomerulonephritis. It was found that the allele frequency and
carriage rate of the interleukin-1 receptor antagonist allele (IL1RN*2) of
the IL-ira gene increased significantly in HSPN patients as compared to
IgAN (P < 0.01), APGN (P < 0.05) and normal subjects (P < 0.01).
Interestingly, varied carriage rates of IL1RN*2 were found among various
groups of IgAN patients presenting with different clinical manifestations.
The carriage rate of IL1RN*2 was significantly higher in patients with
recurrent gross hematuria than other groups of IgAN patients (P < 0.01).
Furthermore, although the carriage rate of 1LIRN*2 was higher in HSPN
(46.5%) than average IgAN patients (26.8%; P < 0.01), there was no
significant difference in the carriage rate of 1L1RN*2 between HSPN and
those IgAN patients with recurrent gross hematuria (42.8%l P > 0.05). It
suggested that the ILl RN*2 allele might be a genetic marker shared by
HSPN and a special group of IgAN patients with recurrent gross hema-
tuna. Our preliminary observation provided a genetic evidence to support
the hypothesis that HSPN and certain subgroup of IgAN are closely
related diseases. Such an association of the gene polymorphism of IL-ira
between HSPN and IgAN with recurrent gross hematuria might serve as
a key to explore their pathogenesis and eventually a specific intervention.
Henoch-Schönlein purpura nephritis (HSPN) and IgA ne-
phropathy(IgAN) share many clinical, histological and immuno-
logical features [1]. The question as to whether HSPN and IgAN
are different clinical manifestations of the same basic disease or if
they are separate entities is yet unanswered. A large body of
clinical and experimental data support the view that IgAN and
HSPN are variants of the same disease process [2]. Although
patients with IgAN lack a skin rash, IgA deposits in dermal vessels
of unaffected skin have been detected, It indicates that, like
HSPN, at least some of the IgAN patients may also present with
extrarenal microvasculitis. The capillary lesion, leukocyte infiltra-
tion, mesangial cell proliferation and crescent formation virtually
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contribute to renal damage in both the HSPN and IgAN. There
are also data suggesting a common genetic background for HSPN
and IgAN [3, 4]. Weiss et al observed the development of IgAN in
the transplanted kidney of patients who had suffered from HSPN
with renal failure [3].
Interleukin-1 (IL-i) has a wide variety of pro-inflammatory and
immunologic actions. Both in vivo and in Vitro studies have
demonstrated that IL-i participates in mesangial cell prolifera-
tion, matrix remodeling, crescent formation, and endothelial cell
activation, promoting intravascular coagulation and leukocyte
adhesion [5]. Several pieces of evidence suggest that IL-i plays a
role in the pathogenesis of IgAN and HSPN. The number of
IL-Irs positive cells infiltrating the glomeruli significantly corre-
lated with mesangial hypercellularity in patients with IgAN [6].
Passive administration of IL-i can induce hematuria in the animal
model of IgAN [7], and recently Wu et al reported that urinary
IL-I activity was increased in both IgAN and HSPN patients [8].
The IL-I receptor antagonist (IL-ira) inhibits IL-i by compet-
ing for receptor binding, and the IL-i activity depends on the ratio
of IL-i to IL-ira. The IL-ira gene is located on the long arm of
human chromosome 2, and a variable number tandem repeats
(VNTR) polymorphism has been characterized in intron 2 of this
gene. This polymorphism has five alleles, comprising between two
and six repeats of an 86-bp sequence. It has been speculated that
individuals carrying two-repeat (IL1RN*2) might have a lower
circulating level of IL-ira in response to inflammation [9, 101.
Since the clinical and renal pathologic changes in patients with
HSPN and IgAN share features associated with IL-i induced
inflammation, in the present study the polymorphisms of the
IL-Ira gene have been analyzed in both of the HSPN and IgAN
patients, to determine the possible genetic linkage between these
two very closely associated diseases. In addition to the normal
subject controls, a group of patients with acute post-infectious
glomerulonephritis (APGN), a disease often presenting gross
hematuria as well, was used as a disease control.
Methods
Patients and controls
Allele frequencies were assessed in 43 patients with biopsy-
proven HSPN (26 males and 17 females, ranging in age from 9 to
23) and 97 patients with biopsy-proven IgAN (67 males and 30
females, ranging in age from 10 to 58). All IGAN patients fulfilled
the pathologic criteria of this disease, manifesting generalized
glomerular mesangial proliferation with predominant IgA depo-
sition, and they were examined to exclude the possibility of
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secondary IgA nephropathy. According to the clinical manifesta-
tions, they were divided into six subgroups [11]: Group rGH,
patients with recurrent gross hematuria (N = 21); Group iGH,
patients with isolated gross hematuria (N = 14); Group Uab,
patients with asymptomatic microscopic hematuria and a modest
amount of proteinuria (< 2 glday; N = 28); Group HUP, patients
with heavy proteinuria, but apparently not nephrotic (N = 7);
Group NS, patients with nephrotic syndrome (N = 8); and Group
HBP, patients with hypertension (N = 19). There were no
differences in the age distribution of patients among these six
groups. Forty-three biopsy-proven HSPN patients all had overt
purpura syndrome and evident renal damage. Ninety-eight nor-
mal subjects (51 males and 47 females, ranging in age from 18 to
55), without renal diseases, were genotyped as control. In addi-
tion, 26 clinical and biopsy-proven acute post-infectious glomer-
ulonephritis (APGN; 14 males and 8 females, ranging in age from
10 to 56) served as a disease control. Patients and normal subjects
were all Han nationality.
PCR analysis
DNA was prepared by standard methods from peripheral blood
leukocyte. Polymerase chain reaction conditions were as follows:
30 cycles at 94°C for one minute, 60°C for one minute, and 72°C
for two minutes, using 5' and 3' primers CTC AGC AAC ACT
CCT AT and TCC TGG TCT GCA GGT AA, which are
immediately flanking the repeat region [9, 10]. The resultant
amplification products were analyzed by electrophoresis on 2%
agarose gels and stained with ethidium bromide for visualization
with UV light. Results of PCR typing of the IL-ira gene poly-
morphism were represented by ILIRN*1 for four repeats (410
bp), IL1RN*2 for two repeats (240 bp), IL1RN*3 for five repeats
(500 bp), IL1RN*4 for three repeats (325 bp), and IL1RN*5 for
six repeats (595 bp) (Fig. 1).
Statistics
Allele frequencies (the number of occurrences of the test allele
in the population divided by the total number of alleles) and
carriage rate (number of individuals carrying at least 1 copy of the
test allele) were calculated. Results from the control and test
groups were compared using the test for statistical significance.
In each group the observed distribution of homozygotes and
heterozygotes conformed to expectations based on Hardy-
Weiberg equilibrium analysis.
Table 1. Allele frequencies for IL-Ira gene in HSPN, IgAN and
controls
IL-ira gene allele
N LIRN*I ILIRN*2 IL1RN°3 ILIRN*4 IL1RN*5
Norma! control 98 0.88 0.12 0 0 0
IgAN average 97 0.86 0.13 0 0.005 0
IgAN with rGH 21 0.78 0.22 0 0 0
HSPN 43 0.64 0.26 0 0.1 0
APGN 26 0.89 0.11 0 0 0
Results
Table 1 showed the distribution of allele frequencies observed
in the HSPN, IgAN, APGN patients and control subjects. The
pattern of four repeats (IL1RN*1) was the most common, fol-
lowed by the two repeats (ILl RN*2), while three repeats occurred
at a much lower frequency, and the five and six repeats were so
rare as not to be represented in this study. There were no
significant differences of the allele frequencies between males and
females in the HSPN, IgAN and APGN patients as well as normal
controls. There was a significant increase in the frequency of
ILl RN*2 allele in patients with HSPN as compared with IgAN
(P < 0.01), APGN (P < 0.05) and normal subjects (P < 0.01).
Obviously, the frequencies of IL1RN*2 allele of the latter three
groups were practically identical (P > 0.05).
The carriage rate of ILl RN*2 was also higher in HSPN patients
(46.5%) than that of IgAN (26.8%; P < 0.05), APGN (19.2%; P <
0.05) and normal controls (24.5%; P < 0.02). The carriage rate for
IL1RN*2 allele in IgAN and APGN patients was not different
from that of normal controls (P > 0.05; Fig. 2).
Interestingly, the frequencies of the IL1RN*2 carrier among
different subgroups of IgAN patients categorized according to
their clinical manifestations were variable, It was found that the
IL1RN*2 carriers were mainly distributed in patients with recur-
rent gross hematuria, it was 35% in Group rGH, 18% in Group
HBP, 15% in Group Uab, 12% in Group NS, 12% in Group HP,
and 8% in Group iGH. The carriage rate of IL1RN*2 was
significantly higher in Group rGH than other subgroups (P <
0.01). Although the carriage rate of IL1RN*2 was higher in HSPN
(46.5%) than the IgAN patients for the whole group (26.8%; P <
0.01), there was no significant difference between the patients of
HSPN and those IgAN patients presenting with recurrent gross
hematuria (42.8%; P> 0.05; Fig. 2).
Discussion
IgA nephropathy is the most common form of glomerulone-
phritis in China, and HSPN represents an important cause of
secondary glomerulonephritis in this country. Most clinical fea-
tures of Henoch-Schönlein purpura are reflections of systemic
leukocytoclastic vasculitis, characteristically affecting the skin,
gastrointestinal tract, and joints. The glomerular damage of this
disease was characterized by two basic lesions: mesangial prolif-
eration and epithelial crescent formation [1]. Capillary and small
blood vessel lesions occur in many cases of HSPN. Immune
complex deposition, predominantly IgA in nature with activation
of complement and consequent leukotaxis, has been considered to
be an important part in its pathogenesis.
Many authors have stated that there are remarkable similarities
between the clinical and pathological aspects of HSPN and IgAN,
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Fig. 1. PCR products of a VNTR polymoiphism in IL-ira gene. Lanes 1, 2,
5, 6, and 7 are four repeat (4!0 bp) homozygotes. Lane 3 is the
heterozygote of four repeats (410 bp) and three repeats (325 bp). Lane 4
is the heterozygote of four repeats (410 bp) and two repeats (240 bp).
Lane 8 is DNA marker ladder of 100 bp.
Fig. 2. The carriage rate of IL1RN*2 allele of
IL-ira gene. Abbreviations are: Normal (normal
control, N = 98); IgAN average (total IgA
nephropathy, N = 97); APGH (acute post-
infectious glomerulonephritis, N = 26); HSPN
(Henoch-SchOnlein purpura nephritis, N = 43)IgAN with and IgAN with rGH (IgAN patients with
rGH recurrent gross hematuria, N = 21).
and it has even been suggested that they are basically the same
entity, except the latter lacks the extrarenal vasculitic manifesta-
tions [12, 13]. Although a familial incidence is unusual, the two
conditions have been reported to coexist in different members of
the same family [4, 14] and even to affect the same patient at
different time [15, 16]. Meadow and Scott [12] reported on two
identical twin brothers. In response to the same viral infection one
developed severe HSPN progressing to chronic renal failure and
the other had IgAN with recurrent hematuria. These observations
indicated that there may be a genetic link between these two
diseases, particularly those cases of IgAN with recurrent gross
hematuria. This hypothesis is also supported by some clinical
evidence. Clarkson, Woodroffe and Aarons studied the age dis-
tribution in IgAN and HSPN patients and found that there were
conspicuous discrepancies between the average age of these two
groups. However, the group of patients with IgAN clinically
characterized by recurrent macroscopic hematuria was frequently
overlapped in age distribution with HSPN as compared with the
other groups. IgAN with recurrent macroscopic hematuria occurs
far more frequently in children and young adults rather than
middle-age or elderly patients [17]. It is also unique that the gross
hematuria of both conditions are frequently preceded by upper
respiratory infection. Skin rash, the cutaneous manifestation of
vasculitis, used to be the clinical hallmark to differentiate primary
IgAN from HSPN. Nevertheless, skin biopsies showed that the
immune complex deposited with equal frequency in normal
appearing and lesional skin of patients with Henoch-Schönlein
purpura [181. Our previous survey in a group of 40 patients of
primary IgAN showed that dermal vascular immunofluorescence
was positive for IgA deposition in about 60.0% of cases showing
gross hematuria, while the remaining cases presented a positive
rate of only 26.0% (P < 0.05) [19]. Based on these factors, it is
speculated that the HSPN and the group of IgAN showing gross
hematuria may in reality be different manifestations of the same
disease process.
Recently, several pieces of evidence suggest that cytokines may
play an important role in the pathogenesis of vasculitis [20]. IL-i
and tumor necrosis factor render the vascular endothelial cells
cultured from the sera of patients with vasculitis susceptible to
lysis by IgG or 1gM antibodies [21]. Since IL-l was strongly
positive in the set of skin lesions in patients with acute Kawasaki
disease, Sato et al assumed that IL-i may play a role in the
inflammation of the skin lesions during acute Kawasaki disease
and may contribute to the rash in the skin [20]. IL-i as an
important component of the inflammatory process in several
glomerular diseases has also been well documented [22, 23]. Thus,
examining the IL-i action system further will probably provide a
new avenue for understanding the pathogenesis of HSPN. The
IL-I receptor antagonist (IL-ira) is structurally homologous to
IL-1 and IL-1. Secreted IL-ira competes equally with both
IL-1 and IL-1 for binding to IL-i receptors. However, binding
of IL-ira does not trigger signal transduction by IL-i receptor
[24]. Recently, a variable number tandem repeats (VNTR) poly-
morphism has been demonstrated in the intron 2 of IL-ira gene
[251.
In the present study, we found that the allele frequency and
carriage rate of ILiRN*2 were significantly higher in patients with
HSPN than patients with IgAN and the normal population.
Interestingly, varied carriage rates of IL1RN*2 were found among
different groups of IgAN patients presenting with different clinical
manifestations. The carriage rate of IL1RN*2 was significantly
higher in patients with recurrent gross hematuria than other
groups of IgAN patients (P < 0.01). Furthermore, although the
carriage rate of IL1RN*2 was higher in I-ISPN (46.5%) than
average IgAN patients (26.8%; P < 0.01), there was no significant
difference in the carriage rate of IL1RN*2 between HSPN and
those IgAN patients with recurrent gross hematuria (42.8%; P>
0.05). To address the question of whether the higher carriage rate
of IL1RN52 is a relatively specific genetic marker for HSPN and
IgAN patients with recurrent gross hematuria, a group of patients
with APGN, a glomerulonephritis known to frequently present
with macroscopic hematuria (31%) [26] were analyzed in the
present study. The allele frequency and carriage rate of the
ILIRN*2 allele in APGN showed no difference from normal
subjects (P> 0.05), but were much lower than those with HSPN
(P < 0.05). This is also consistent with our previous observation in
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lupus nephritis [27], in which the allele frequency and carriage
rate of ILIRN*2 made no differences when compared with
normal control (P > 0.05). Taken together, these data indicate
that the high carriage rate of ILIRN*2 is not an common
phenomenon in glomerular diseases with macroscopic hematuria
and vasculitis.
As what has been noted that the very unique clinical feature of
IgAN is the tremendous interindividual variation in both the
clinical manifestations and the rate of progression of glomerulo-
sclerosis [28, 29]. Obviously, it is difficult to work out the possible
common pathogenesis between HSPN and IgAN disregarding the
various groups of clinical manifestations. The data presented
herein show that the carriage rate of ILl RN*2 in HSPN is higher
than that of the IgAN on average, but it is very close to the group
of IgAN patients with recurrent gross hematuria. As discussed
previously, these two groups of patients are very much like each
other both pathologically and clinically. It is therefore suggested
that the high carriage rate of the IL1RN*2 allele in the IL-Ira
gene might be a genetic marker shared by HSPN and IgAN
patients with recurrent gross hematuria. Such a similarity in the
gene background may be responsible for the common clinical
features seen in HSPN and IgAN patients with recurrent gross
hematuria. It alsu provides an important evidence to support the
hypothesis that recurrent gross hematuria in IgAN is actually a
subclinical type of HSPN per Se, which is clinically diagnosed
mainly upon the presence of purpura. Montinaro et al reported
that passive administration of IL-I can induce hematuria in an
animal model of IgAN [7]. In these mice, glomerular IgA immune
deposits were induced by administration of anti-phosphoryicho-
line (PC) with either a PC-containing carbohydrate antigen of
pneumococcal C polysaccharide or a protein antigen of PC-
conjugated bovine serum albumin. The authors also showed that
IL-I treated control mice did not produce hematuria [7]. Their
observation suggests that in IgAN the rapid onset of hematuria
coincident with a microbial infection could be due to the elicita-
tion of the mesangial lesion through the extrarenal cyctokines
produced by the infection.
The notion that the gene polymorphism may be responsible for
the clinical feature and the progression of disease is both intrigu-
ing and provocative. Considering the biological activities of IL-i,
the IL-ira gene itself is a plausible candidate for a role in
glomerulonephritis and vasculitis. We, for the first time, postulate
that the association of ILIRN*2 allele of IL-Ira gene in HSPN
and IgAN presenting recurrent gross hematuria might be a
genetic link between these two groups of patients. The polymor-
phism may be associated with the altered gene function or merely
he acting as a chromosomal marker for another gene. Since we
have not measured the serum level of IL-ira in individuals with
different genotype of IL-Ira, it is difficult to refer the functional
significance of ILl RN*2 allele in HSPN and in IgAN patients with
recurrent gross hematuria in this preliminary study. It has been
recognized that heritable factors, in combination with a number of
environmental risk factors, are important determinants of the
pathogenesis and natural history of IgAN and HSPN. In addition,
it should be kept in mind that for such polygenic diseases, a much
more complicated genetic mechanism(s) might contribute to the
clinical manifestations and the progression of the diseases. Fur-
ther investigation of the functional significance of the IL-ira
polymorphism and its impact on the progression of HSPN and
IgAN might lead to a new avenue to a specific intervention
therapy in future.
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